SUZHOU, China – On the eve of a key biopharmaceutical partnering fest – the Chinabio Partnering Forum begins here today – BioWorld Asia took a closer look at what it takes for successful dealmaking in the most populous nation on earth. The experts all agree: the landscape for licensing in China is getting more crowded with competitors. Read More
Preferring engagement to extreme censure, the U.S. Trade Representative (USTR) hopes to work with officials in China and India this year to create a more even playing field for U.S. medical products in those markets. Read More
HONG KONG – International researchers led by the Shanghai Institute of Materia Medica (SIMM) at the Chinese Academy of Sciences have mapped the detailed structure of a receptor with a key role in platelet activation and blood clotting, which has important implications for development of new treatments for cardiovascular and possibly other diseases. Read More
SUZHOU, China – With the 6th Chinabio Partnering Forum happening this week – designed to foster cross-border partnering – the event is considered the best place for the world to meet up-and-coming Chinese life science companies. Several trends driving partnering this year promise to make the event the liveliest yet. Read More
HONG KONG – Ambrx Inc. and Zhejiang Hisun Pharmaceuticals Co. Ltd. (SH:600267) inked a deal to develop and commercialize bispecifics based on Ambrx's research with an aim to develop new oncology therapies. Read More
HONG KONG – With the release of first quarter earnings reports from three major Chinese biopharmaceutical companies, a variety of different opportunities and challenges in the mainland market were highlighted, as well as the growing importance of mergers and acquisition (M&A) to the bottom lines of companies in this increasingly competitive market. Read More
Beigene Co. Ltd., of Beijing, received a $5 million milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck KGaA, of Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in phase I development. The milestone triggers a $5 million payment from Merck to Beigene. Read More
Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., was issued Japanese Patent Nos. 5443763 and 5457196, which are related to pharmaceutical formulations of sapacitabine and methods of treating cancer comprising sapacitabine in combination with histone deacetylase inhibitors, respectively. Read More
